Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 2/20 | 0.41 |
| ▸ | SLC29A1 | Q99808 | 3/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29601247 | 0.85 | SLC29A1 (0.39) | NT5ESLC29A1CYP2C19ALDH1A1TSHR | |
| SCHEMBL29601167 | 0.81 | ALDH1A1 (0.36) | NT5EALDH1A1TSHRMAPK8ADORA3 | |
| SCHEMBL22912673 | 0.79 | CYP2C19 (0.33) | SLC29A1CYP2C19HDAC1HDAC2ADORA3 | |
| SCHEMBL29601214 | 0.78 | SLC29A1 (0.43) | NT5ESLC29A1CYP2C19HDAC1HDAC2 | |
| SCHEMBL29601224 | 0.76 | HDAC1 (0.58) | HDAC1HDAC2ADORA3CDK1 | |
| SCHEMBL22912745 | 0.75 | SLC29A1 (0.42) | NT5ESLC29A1CYP2C19HDAC1HDAC2 | |
| SCHEMBL5694226 | 0.72 | CDK1 (0.59) | ADORA3CDK1 | |
| SCHEMBL29601208 | 0.68 | HDAC1 (0.43) | HDAC1HDAC2ALDH1A1 | |
| SCHEMBL29601423 | 0.68 | ALDH1A1 (0.36) | ALDH1A1TSHRMAPK8 | |
| SCHEMBL29601213 | 0.68 | HDAC1 (0.42) | HDAC1HDAC2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3997089-A1 | CYSTEINE BINDING COMPOSITIONS AND METHODS OF USE THEREOF | University Of Virginia Patent Foundation (US) | 2022-05-18 | — | — | EP | claimed |
| US-20220251085-A1 | CYSTEINE BINDING COMPOSITIONS AND METHODS OF USE THEREOF | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2022-08-11 | — | — | US | disclosed |
| EP-3997089-A1 | CYSTEINE BINDING COMPOSITIONS AND METHODS OF USE THEREOF | University Of Virginia Patent Foundation (US) | 2022-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251085-A1 | CYSTEINE BINDING COMPOSITIONS AND METHODS OF USE THEREOF | DDB1, HSPBP1, ATIC | NT5E 636/4885SLC29A1 301/4885CYP2C19 3954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.